In this study of 118,187 tumor samples from a de-identified database, including a subset of 2039 samples from a clinically annotated database, the prevalence of PD-L1 amplification was 0.7%. The objective response rate for patients with solid tumors that harbored PD-L1 amplification was 66.7%, with a median progression-free survival of 15.2 months. The results of this study suggest that PD-L1 amplification occurs in a small subset of malignant tumors; however, testing for this alteration may be warranted because of the frequent and durable responses to PD-L/PD-L1 blockade.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2684636
